Serum Carbonic Anhydrase 9 (CA9) Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer : a Pilot Study
We propose a pilot study of CA9 serum in patients with adenocarcinoma metastatic cell
treated by conventional immunotherapy and / or targeted therapy. This pilot study aims to
test the CA9 serum marker of response to medical treatment
Observational
Observational Model: Cohort, Time Perspective: Prospective
serum protein CA9 and mRNA CA9 level under medical treatment
before treatment, at 1, 3, 6, 9 and 12 months
No
Jacques TOSTAIN, MD-PhD
Study Director
CHU de Saint-Etienne
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
0808071
NCT00942058
June 2009
November 2013
Name | Location |
---|